vWD


Also found in: Acronyms.

Willebrand disease

, von Willebrand disease (vil′ĕ-brant″)
[Erik Adolph von Willebrand, Finnish physician, 1870–1949]
,

vWD

A congenital autosomal dominant bleeding disorder caused by a deficiency of von Willebrand factor (a protein that helps platelets stick to injured blood vessels during the formation of blood clots. Inadequate amounts of the protein result in easy bruising or bleeding. Common symptoms of the disorder are frequent bleeding from the gums after brushing the teeth, frequent or prolonged nosebleeds, heavy menstrual periods, or heavy bleeding after childbirth or surgery.

The disease is the most common inherited bleeding disorder. Unlike hemophilia A and B, which are X-linked, it affects both genders. Despite its high prevalence in the population (about 3% of Americans are affected), vWD is often undiagnosed because many affected people have only mild episodes of bleeding. vWD can be diagnosed by the demonstration of low levels of von Willebrand factor in the blood; by a prolonged bleeding time; or by factor VIII deficiency (one function of von Willebrand factor is to carry clotting factor VIII in plasma). Treatments for heavy bleeding episodes (or for necessary surgeries) may include the administration of clotting factors containing von Willebrand factor or factor VIII or synthetic vasopressin.

References in periodicals archive ?
In various published series, 32%-100% of women with von Willebrand disease (VWD), the most common inherited bleeding disorder, were reported to have heavy menstrual bleeding.
In general, most patients with vWD do not require prophylactic replacement therapy, especially for Type 1 disease or if the ristocetin cofactor levels are more than 50% of normal.
It has previously been shown that amino acid substitutions R1306W, R1308C, V1316M, and R1341Q account for 90% prevalence of the subtype 2B VWD [6, 8].
epistaxis particularly lasting for more than 30 min, causing anaemia or hospital admission seen in platelet disorders, VWD (Grade C, level IV).
Willfact is a plasma-derived human von Willebrand factor (vWF) concentrate used to stop and prevent bleeding in severe vWD patients.
Using our standard test processes for VWD investigation and LTA without adjustment of PRP platelet count, 2/9 (22%) of these cases were identified to have possible mild platelet dysfunction, 1/9 (11%) possible mild type 1 VWD, and 1/9 (11%) possible mild type 1 VWD plus moderate platelet dysfunction.
From an epidemiologic standpoint, the clinical course of the disease (3 weeks), age of affected pigs (<3 weeks), and clinical signs were in agreement with those of VWD caused by PHE-CoV (3,8,13).
Erik von Willebrand first described inherited von Willebrand disease (vWD) in 1926, when he documented an autosomal-dominant pattern of inheritance of excessive bleeding (as opposed to X-linked transmission that characterises the common 2 types of haemophilia) in a family from the Aland Islands in the Gulf of Bothnia.
This clotting factor concentrate is the first biologic product approved for patients with von Willebrand disease (vWD) who are undergoing surgery or invasive procedures and for whom desmopressin is either ineffective or contraindicated, according to the FDA.
* Special Considerations: The product is not approved for people with severe vWD (type 3) undergoing major surgery.
However, with the introduction of new Medicare/Medicaid "dual eligible" plans and the increasing diagnoses of blood illnesses such as von Willebrand disease (vWD), a blood clotting disease, MA plans may see increasing claims in this area.